Navigating the Changing Landscape of Relapsed/Refractory Multiple Myeloma: Optimizing Treatment Strategies : Episode 3
R/R MM: Bispecifics in R/R MM: Key Takeaways
Panelists discuss how to manage talquetamab-associated adverse events, such as skin toxicities and dysgeusia, sharing their clinical experience with toxicity timing, frequency, and key strategies for fellow oncologists implementing bispecific antibodies in relapsed/refractory multiple myeloma.
Video content above is promoted by the following;
- What are your current strategies for managing AEs (skin toxicities, dysgeusia, etc) seen with talquetamab?
- When do these toxicities typically appear, and how often do you see them in practice?
- Please share your key takeaways from that meeting, especially surrounding the use of bispecifics (dosing, AE management) in R/R MM.
- What clinical pearls can you share for fellow medical oncologists considering the use of bispecifics in R/R MM?
Recent Videos
Related Content
